(Q38306880)

2 September 2017

1 reference

title

Emerging drugs for squamous cell lung cancer (English)

1 reference

2 September 2017

1 reference

Haiying Cheng

1 reference

2 September 2017

Marina Shcherba

1 reference

2 September 2017

Karthikeya Kandavelou

1 reference

2 September 2017

Yuanxin Liang

1 reference

2 September 2017

Huijie Liu

1 reference

2 September 2017

Roman Perez-Soler

1 reference

2 September 2017

language of work or name

English

0 references

publication date

5 January 2015

1 reference

Expert Opinion on Emerging Drugs

2 September 2017

published in

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

149-160

1 reference

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

PIK3CA mutation and amplification in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Personalized therapy on the horizon for squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1001365

10.1517/14728214.2015.1001365

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference